^
Association details:
| Biomarker: | KIT mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DRUG REPOSITIONING OF CABOZANTINIB TO TREATMENT OF LEUKEMIC CELLS WITH RUNX1-RUNX1T1 AND KIT MUTATION
Published date:
05/14/2020
Excerpt:
Cabozantinib demonstrated a favorable effect in AML cells harboring t(8;21) and KIT mutation from both in vitro and in vivo aspects.
